An expeditious microwave-assisted synthesis of 4BP-TQS, its enantiomeric separation and their functional evaluations is reported. Electrophysiological characterization in Xenopus oocytes revealed that activity exclusively resided in the (+)-enantiomer 1b (GAT107) and (−)-enantiomer 1a did not affect its activity, when co-applied. X-ray crystallography studies revealed the absolute stereochemistry of 1b to be 3aR, 4S, 9bS. Compound 1b represents the most potent ago-PAM of α7 nAChRs available to date and is considered for further in vivo evaluation.
INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs), members of Cys-loop superfamily of cationic ligand-gated ion channels are involved in the physiological responses to the neurotransmitter acetylcholine (ACh) and are distributed throughout the central and peripheral nervous systems. [1] [2] Several distinct nAChR subtypes have been identified based on subunit composition and stoichiometry. 3 The homopentameric α7 nAChR subtype is distinguished from the other nAChRs by its relatively high permeability to Ca +2 , rapid activation and desensitization (<100 ms) following exposure to agonists and sensitivity to antagonists such as α-bungarotoxin and methyllycaconitine. 4, 5 It has been considered a promising target for improving cognitive impairments in diseases such as Alzheimer's (AD) and schizophrenia 6 as well as for treatment of inflammation and neuropathic pain. 7 In recent years, a variety of structurally distinct, subtype-selective and potent α7 nAChR agonists have been developed and profiled. 8 However, rapid desensitization of α7 nAChRs in response to high agonist concentration in vitro 9 together with the possibility of endogenous tone disruption 10 has led to concerns regarding utility of such agonists as clinical candidates. 2 An alternative therapeutic approach has been the development of positive allosteric modulators (PAMs) which can synergize and augment orthosteric-site-mediated signaling of endogenous neurotransmitter ACh without, in most cases, directly activating or desensitizing the receptor. 11 Selective PAMs of α7 nAChR have been reported and classified as type I and type II (Figure 1) . 11, 12 Type I PAMs increase peak agonist-evoked responses but have little or no effect on the decay rate of macroscopic currents or the equilibrium desensitization of α7 nAChR, 13 whereas type II PAMs increase peak currents as well as slow down the apparent desensitization profile of the agonist response. 12, 14, 15 Both types of PAMs have been reported to show in vivo efficacy in animal model of cognition, however, only type II PAMs are efficacious in neuropathic pain models. 16 Additional PAMs displaying the properties intermediate to the type I and type II have also been identified. 17, 18 Recently, 4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H cyclopenta[c]quinoline-8-sulfonamide (1, 4BP-TQS, Figure 1 ), a substituent analog of TQS, was shown to possess allosteric agonism in addition to type II PAM activity (ago-PAM). 19, 20 Compound 1 was shown to cause agonism through a site topographically distinct from the ACh site and was a more potent and efficacious agonist of α7 nA-ChR than ACh (8-fold lower EC 50 and 45-fold larger maximal response). 19 Acting as an allosteric agonist, 1 produced less equilibrium desensitization than would be seen with orthosteric agonists. A relatively slow-desensitizing allosteric agonist might be particularly beneficial compared to a ligand with only PAM activity, under conditions of severe loss of endogenous acetylcholine, such as in advanced Alzheimer's disease. Although, several examples of ago-PAMs have been reported for Gprotein coupled receptors, availability of such modulators for ion-channel receptors is limited.
Compound 1 is by far the most potent ago-PAM of α7 nAChR available for investigating the effect of such modulation in biological system. 20 However, it has been studied exclusively in vitro as a racemate. 19, 20 It has three chiral centers with the cyclopentene and 4-bromophenyl rings oriented cis-to each other. Neither the individual contributions of each enantiomer towards racemate's dual activity (ago-PAM) at α7 nAChR nor the effect of presence of one enantiomer on the activity of the other is known.
In this work, we have developed an expeditious, microwave-assisted synthesis of 1, performed separation of its enantiomers followed by their functional evaluations and identified the (+)-enantiomer 1b (GAT107) as the bioactive enantiomer having 3aR, 4S, 9bS absolute stereochemistry.
RESULT AND DISCUSSION

Chemistry
The tetrahydro-3H-cyclopenta[c]quinoline scaffold of 1 is synthetically accessible using the three-component Povarov cyclization (aza-Diels-Alder reaction). 21, 22 The reaction between 4-aminosulfonamide, 4-bromobenzaldehyde and cyclopentadiene in the presence of 20 mole % InCl 3 at room temperature, over 24 hour was reported to give the desired product in only 37% yield and the cis-diasteromer 1 was reported to be the major product. 20 We recently developed a microwave-accelerated and high yielding synthesis of cyclopentene ring-fused tetrahydroquinolines. 23 In this work, we extend the application of this methodology to the synthesis of 1. Our optimized procedure employed InCl 3 (20 mole%) in acetonitrile, for 15 minutes at 100°C under microwave irradiation, which gave 1 in 70% yield and cisdiasteromer was obtained exclusively (Scheme 1). The reaction conditions were highly reproducible and 1 could easily be scaled-up to multi-gram quantities. Compound 1 contains three chiral centers and the cis-stereochemical orientation of cyclopentene and 4-bromophenyl rings was confirmed based on the coupling constant between protons H-3a and H-4 (J 3a,4 = 3.5Hz; see Experimental) in 1 H NMR.
Enantiomeric resolution of racemate 1 was undertaken by chiral HPLC. Several analytical conditions were tried, and a hexane/ethanol (60:40) mixture as a mobile phase with Chiralpak IA was found to provide baseline separation of two enantiomers (see SI Fig. 1 ). These optimized conditions were used for enantiomeric excess determination and were further extended to the preparative method for separation of enantiomer pair 1a and 1b. The preparative chiral HPLC method was scaled up for the separation of gram quantities of racemic 1 to provide enantiomer 1a and 1b in > 99% enantiomeric excess (ee).
The CD spectra of the enantiomers of 1 were measured using their solutions in chloroform (2.45 mM for 1a and 2.55 mM for 1b) and were mirror images of each other, thus, confirming their enantiomeric nature (See SI, Fig. 2 ). Enantiomers exhibited a strong Cotton effect at shorter wavelength (272 nm). The structure of 1b was established using 1D NMR spectra as well as 13 C NMR, DQ-COSY, HSQC, HMBC and ROESY correlations (see SI).
In-vitro Biological Evaluation
Functional characterization of enantiomers in Xenopus oocytes-Oocytes expressing human α7 nAChR were studied with two-electrode voltage clamp (see Methods in SI). 24 Cells were given control applications of 60 µM ACh and then treated with 10 µM of 1a or 1b. As shown in Figure 2A , 1a neither evoked a response nor significantly enhanced the size of responses evoked by subsequent applications of ACh at the control concentration. Likewise, co-application of 1a with ACh did not potentiate ACh evoked responses. In contrast, 1b was very effective both as an allosteric agonist when applied alone and as a PAM when co-applied with ACh. Note also that the potentiating effects of 1b were long lasting, suggesting that it may remain bound to receptors after bath applications, such that there was very good potentiation of responses to the application of ACh alone four minutes after the application of 1b alone. During this wash period, currents returned to baseline but receptors nonetheless remained primed for potentiated ACh responses.
Concentration dependence of 1b: allosteric activation and potentiation-Using our standard 20-second application protocol, we evaluated the concentration-response relationship for 1b-evoked net-charge response. 24 With this protocol we estimated an EC 50 of 28 ± 3 µM ( Figure 2B ). The potentiation of subsequent ACh-evoked responses showed similar concentration dependence. It should be noted that these data are based on relatively brief applications of 1b, and since the potentiating effects are only slowly reversible, it is likely that the potency for allosteric activation and potentiation might be increased with longer incubations.
Enantiomer competition and potentiation time course-In order to determine whether the inactive enantiomer might function as a competitive antagonist of 1b, oocytes were treated with either 10 µM 1b alone or in combination with 10 µM 1a. As shown in Figure 3A , neither the allosteric activation (t = 0), nor the potentiation of subsequent AChevoked responses by 1b were reduced when 1a was co-applied with the active isomer. In this experiment two pre-incubation times were tested, 30 seconds and 5 minutes. As expected, the longer incubations produced greater allosteric activation and larger potentiation of the subsequent ACh-evoked responses. The decay rate of the 1b potentiation was too slow to measure over the course of 20 minutes.
Comparison of 1b to racemic 1-Although our data indicate that the inactive isomer is not a competitive antagonist of 1b, a racemic preparation of 1 would be expected to have less activity than the purified preparation of 1b at the same concentration. As shown in Figure 3B , the potentiating activity of 30 µM of 1 co-applied with 300 µM of the α7-selective agonist choline was significantly less than that of 30 µM 1b.
X-ray crystal structure-To define the absolute configuration of C3a, C4 and C9b, we explored different crystallization conditions for bioactive enantiomer 1b. Crystals suitable for X-ray investigation were obtained when compound 1b was crystallized from CH 2 Cl 2 . As shown in Figure 4 , the stereochemistry of the active enantiomer was confirmed to be cis and the absolute configuration was revealed to be 3aR, 4S, 9bS.
CONCLUSION
In conclusion, we have developed a novel, microwave-accelerated synthesis of 4BP-TQS and performed separation of its enantiomer using chiral HPLC. The second eluted (+)-enantiomer 1b was shown to possess almost all α7 ago-PAM activity, whereas, the (−)-enantiomer 1a had negligible activity as an allosteric agonist or as a PAM and it did not affect activity of enantiomer 1b when applied together. X-ray crystallography studies revealed the absolute stereochemistry of the active enantiomer 1b to be 3aR, 4S, 9bS. This critical information will be valuable for further lead optimization efforts. Compound 1b represents the most potent ago-PAM of α7 nAChR available to date, and is a valuable tool to investigate the biological functions controlled by α7 nAChR both in vitro and in vivo.
EXPERIMENTAL SECTION Chemistry
All commercial chemicals and solvents were purchased from Sigma-Aldrich Inc. and Alfa Aesar and unless otherwise specified they were used without further purification. Biotage Initiator microwave system was used for the synthesis. The progress of the reaction was monitored by thin layer chromatography (TLC) using commercially prepared silica gel 60 F 254 glass-backed plates. All compounds were visualized under ultraviolet (UV) light. NMR spectra and other 2D spectra were recorded in DMSO-d 6 , unless otherwise stated, on a Varian 500MHz. Chemical shifts are recorded in parts per million (δ) relative to internal tetramethylsilane (TMS). Multiplicities reported in Hertz (Hz). LCMS analysis was performed using a Waters Alliance reverse-phase HPLC, (electrospray ionization). The CD spectra of enantiomers (dissolved in CHCl 3 ) were measured on a Jasco J-815 CD spectropolarimeter. Specific rotations of enantiomers were measured at 589 nm with a Jasco polarimeter model P-2000 equipped with a Na lamp. The volume of the cell was 100 mm and were specific rotations were recorded in methanol (c = 1.0).
4-(4-Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (1)
In a microwave vial, cyclopentadiene (2.14 g, 32.43 mmol, 3 equiv.) was added to a suspension of 4-bromobenzaldehyde (2 g, 10.81 mmol), 4-aminosulfonamide (1.86 g, 10.81 mmol) and indium trichloride (476 mg, 2.15 mmol, 0.2 equiv.) in acetonitrile (15 mL). The reaction vial was placed in a microwave synthesizer and heated to 100°C for 15 min. The contents were added to aqueous Na 2 CO 3 solution (0.1 M; 30 mL) and extracted with chloroform (3×50 mL). The combined organic layer was washed with water (20 mL), brine (30 mL), and (Na 2 SO 4 ) and concentrated under reduced pressure. The residue was purified by chromatography (EtOAc/Hexane = 20/80 → 50/50) to yield compound 1 as a white solid (3.07 g; yield 70%). See SI for the details of enantiomer separation and characterization. (A) Extended pre-incubations with 1b produced greater allosteric activation and increased the potentiation of ACh-evoked responses by 1b. These effects were not significantly affected when 1a was co-applied, suggesting that 1a is not a competitive antagonist of the active isomer. Data were normalized to the average of two responses evoked by ACh alone prior to the application of compounds 1a and 1b. The points represent the average responses of at least four oocytes to either the GAT compounds alone (at t = 0) or the application of 60 µM ACh (all other points). Note that although the responses to 5 minute incubations had both transient and sustained components, the data plotted are for the standard 120-second interval beginning with the start of drug application. (B) The potentiating activity of 1b compared to 1. Oocytes expressing α7 were evaluated for responses to control applications of 60 µM ACh and then incubated with 300 µM choline and either 1b or 1 at the indicated concentrations. Net-charge responses were calculated for the entire 5-minute incubation periods. Data were normalized to the average of two responses evoked by ACh alone prior to the application of the choline and PAMS. The bars represent the average responses of at least 4 oocytes The molecular structure of 1b as determined by x-ray diffraction. For clarity only one of the two molecules in the asymmetric unit is shown; displacement ellipsoids are at the 50% level. Improved synthesis of compound 1
